Purdue’s Thompson: Lomustine establishes proof of principle for resolving cancer drug shortages

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

David H. Thompson, a professor at the Department of Chemistry at Purdue University and a member of the Purdue Center for Cancer Research, is working on a better and faster way to produce drugs and eliminate shortages.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Paul Goldberg
Editor & Publisher

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.
Paul Goldberg
Editor & Publisher

Login